|
시장보고서
상품코드
2040835
DNA 제조 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 등급별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)DNA Manufacturing Market Size, Share & Trends Analysis Report By Type (Plasmid, Synthetic), By Grade (GMP, R&D), By Application (Cell & Gene Therapy, Vaccines), By End Use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
DNA 제조 시장 요약
세계의 DNA 제조 시장 규모는 2025년에 64억 달러로 추계되며, 2033년까지 231억 달러에 달할 것으로 예측됩니다.
2026-2033년 CAGR 17.8%로 성장할 것으로 예상됩니다. 이러한 성장은 유전자 치료 및 맞춤형 의료에 대한 수요 증가와 합성생물학의 발전에 힘입어 성장하고 있습니다.
제약 연구개발 및 백신 개발에서의 용도 확대도 시장 확대에 기여하고 있습니다. 예를 들어 2024년 7월, GenScript Biotech는 생산 시간을 단축하고 유전자 치료 및 합성 백신 개발을 가속화할 수 있는 첨단 DNA 합성 플랫폼의 출시를 발표했습니다.
유전자 치료의 성장
유전자 치료는 유전질환, 희귀질환 및 일반적인 만성질환의 치료 방식을 변화시키고 있습니다. 유전자 치료는 환자 세포내 결함이 있는 유전자를 직접적으로 변형 또는 대체하여 장기적인 효과와 근본적인 효과를 가져올 수 있는 잠재력을 가지고 있습니다. 예를 들어 2022년 9월 GenScript USA Inc.는 T 세포 공학에서 CRISPR 기반 유전자 편집을 강화하기 위해 고안된 'GenWand double stranded DNA(dsDNA)' 서비스를 도입했습니다. 이 서비스는 공유결합으로 폐쇄된 선형 DNA 템플릿을 제공합니다. 이는 기존의 PCR 기반 방식에 비해 안정성이 높고, 엔도뉴클레아제에 의한 분해가 적어 상동성 의존적 복구(HDR)의 효율을 향상시키고, 오프타겟 효과를 감소시킵니다. 이 혁신적인 접근법에서는 환자의 세포에 교정 유전자를 도입하는 바이러스 벡터나 플라스미드와 같은 치료용 벡터를 개발하기 위해 고정밀, 고순도의 DNA 서열을 대규모로 생산해야 합니다.
예를 들어 2024년 11월 NewBiologix는 'Xcell rAAV 생산 및 분석 플랫폼'을 출시했습니다. 이 플랫폼은 여러 rAAV 후보물질의 동시 스크리닝을 가능하게 하며, 전임상 및 임상 개발을 지원하는 포괄적인 데이터 보고를 제공합니다. 주요 기능으로는 완전캡시드와 빈캡시드의 비율과 유전자 서열의 완전성을 포함하여, 유전자 치료제 개발을 가속화할 수 있는 인캡슐레이션 DNA의 상세한 특성 평가가 있습니다. 더 많은 유전자 치료제가 임상시험을 거쳐 규제 당국의 승인을 받으면서 DNA 제조에 대한 수요가 급증하고 있습니다. 각 치료에 필요한 복잡성과 맞춤형으로 인해 고품질 DNA를 대규모로 신속하게 생산할 수 있는 첨단 DNA 합성 기술에 대한 요구가 증가하고 있습니다. 척수성 근위축증, 특정 유전성 실명, 베타-지중해빈혈과 같은 혈액질환과 같은 질환에서 유전자 치료의 성공사례가 보고되고 있으며, 이는 DNA 제조 시장의 확대를 견인하고 있습니다.
자동화 및 품질 향상
기술의 발전과 자동화는 정확도를 향상시키고 비용을 크게 절감함으로써 DNA 제조 산업에 혁명을 일으키고 있습니다. 실리콘 기반 DNA 합성, 마이크로 유체 기술, AI를 활용한 설계 툴 등의 혁신을 통해 정확성과 재현성을 높인 고처리량 생산이 가능해졌습니다. 예를 들어 2023년 11월 Twist Bioscience는 자사의 실리콘 기반 플랫폼과 확장된 제조 능력을 활용하여 NGS로 검증된 복제 유전자를 5-7일 이내에 제공하는 신속한 유전자 합성 서비스인 'Express Genes'를 출시했습니다.
시퀀싱 기술과 바이오인포매틱스의 발전으로 품질관리 프로세스가 더욱 효율화되어 합성 DNA 제품이 항상 임상 및 연구용으로 필요한 엄격한 기준을 충족할 수 있도록 보장합니다. 예를 들어 2025년 3월, WuXi Biologics는 재조합 단백질 및 플라스미드 DNA의 생산을 강화하기 위해 고수율, 안정성, 확장성 및 비용 효율적인 제조를 위해 설계된 대장균 기반 시스템 "EffiX 플랫폼"을 도입했습니다. 이 플랫폼은 다양한 생물의약품 제제의 효율적인 개발 및 제조를 지원합니다. 자동화 및 첨단 기술의 지속적인 도입으로 복잡한 DNA 염기서열의 신속하고 고품질의 대규모 생산이 가능해짐에 따라 시장 상황이 변화하고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 개요
제3장 시장 : 변수, 동향, 범위
제4장 DNA 제조 시장 : 유형별 비즈니스 분석
제5장 DNA 제조 시장 : 등급별 비즈니스 분석
제6장 DNA 제조 시장 : 용도별 비즈니스 분석
제7장 DNA 제조 시장 : 최종 사용별 비즈니스 분석
제8장 지역별 DNA 제조 시장 : 지역별 추정·동향 분석
제9장 경쟁 구도
KSA 26.06.02DNA Manufacturing Market Summary
The global DNA manufacturing market size was estimated at USD 6.4 billion in 2025 and is anticipated to reach USD 23.1 billion by 2033, growing at a CAGR of 17.8% from 2026 to 2033. This growth is driven by increasing demand for gene therapies, personalized medicine, and advancements in synthetic biology.
Expanding applications in pharmaceutical research and vaccine development also contribute to market expansion. For instance, in July 2024, GenScript Biotech announced the launch of an advanced DNA synthesis platform that reduces production time, enabling faster development of gene therapies and synthetic vaccines.
Growth of Gene Therapy
Gene therapies are transforming the treatment landscape for genetic disorders, rare diseases, and common chronic conditions. Gene therapies directly modify or replace faulty genes within a patient's cells, offering the potential for long-lasting or curative effects. For instance, in September 2022, GenScript USA Inc. introduced the GenWand Double-Stranded DNA (dsDNA) service, designed to enhance CRISPR-based gene editing in T-cell engineering. This service offers covalently closed, linear DNA templates that are more stable and less prone to endonuclease degradation, thereby improving homology-directed repair (HDR) efficiency and reducing off-target effects compared to traditional PCR-based methods. This innovative approach requires large-scale production of highly precise, pure DNA sequences to develop therapeutic vectors, such as viral carriers or plasmids, that deliver corrective genes into patient cells.
For instance, in November 2024, NewBiologix launched its Xcell rAAV Production and Analytics Platform. It enables simultaneous screening of multiple rAAV candidates and provides comprehensive data reports that support preclinical and clinical development. Key features include detailed characterization of encapsulated DNA, including full and empty capsid ratios and gene sequence integrity, to accelerate gene therapy development. As more gene therapies progress through clinical trials and receive regulatory approvals, the demand for DNA manufacturing grows exponentially. The complexity and customization required for each treatment drive the need for advanced DNA synthesis technologies capable of producing high-quality DNA at scale and speed. Diseases like spinal muscular atrophy, certain types of inherited blindness, and blood disorders such as beta-thalassemia have experienced successful gene therapy treatments, fueling the market expansion of DNA manufacturing.
Automation and Grade Improvements
Technological advancements and automation are revolutionizing the DNA manufacturing industry by improving accuracy and significantly reducing costs. Innovations such as silicon-based DNA synthesis, microfluidics, and AI-powered design tools enable high-throughput production with enhanced precision and reproducibility. For instance, in November 2023, Twist Bioscience launched Express Genes, a rapid gene synthesis service delivering NGS-verified clonal genes within five to seven days, leveraging its silicon-based platform and expanded manufacturing capacity.
Improvements in sequencing technologies and bioinformatics have further streamlined quality control processes, ensuring that synthetic DNA products consistently meet the stringent standards required for clinical and research use. For instance, in March 2025, WuXi Biologics introduced the EffiX platform, an E. coli-based system designed to enhance recombinant proteins and plasmid DNA production, delivering high yield, stability, scalability, and cost-efficient manufacturing. This platform supports the efficient development and manufacturing of diverse biologics modalities. The continued adoption of automation and advanced technologies is transforming the market landscape by enabling rapid, high-quality production of complex DNA sequences at scale.
Global DNA Manufacturing Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global DNA manufacturing market based on type, grade, application, end use, and region:
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Plasmid DNA
- Synthetic DNA
- Gene Synthesis
- Oligonucleotide Synthesis
- Grade Outlook (Revenue, USD Million, 2021 - 2033)
- GMP Grade
- R&D Grade
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Cell & Gene Therapy
- Vaccines
- Oligonucleotide-based Drugs
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Pharmaceutical and Biotechnology Companies
- Academic & Research Institutes
- Contract Research Organizations
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Type
- 1.2.2. Grade
- 1.2.3. Application
- 1.2.4. End Use
- 1.3. Information analysis
- 1.4. Market formulation & data visualization
- 1.5. Data validation & publishing
- 1.6. Information Procurement
- 1.6.1. Primary Research
- 1.7. Information or Data Analysis
- 1.8. Market Formulation & Validation
- 1.9. Market Model
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Growth of Gene Therapy
- 3.2.1.2. Automation and Grade Improvements
- 3.2.1.3. Expansion of mRNA Vaccine Development
- 3.2.2. Market restraint analysis
- 3.2.2.1. High Production Costs
- 3.2.2.2. Complex Regulatory and Quality Compliance
- 3.2.3. Market Challenges Analysis
- 3.2.4. Market Opportunity Analysis
- 3.2.1. Market driver analysis
- 3.3. Case study insights
- 3.4. DNA Manufacturing Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's Five Forces Analysis
- 3.4.2. PESTEL Analysis
Chapter 4. DNA Manufacturing Market: Type Business Analysis
- 4.1. Type Segment Dashboard
- 4.2. Global DNA Manufacturing Market Type Movement Analysis
- 4.3. Global DNA Manufacturing Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
- 4.4. Plasmid DNA
- 4.4.1. Global Plasmid DNA Market, 2021 - 2033 (USD Million)
- 4.5. Synthetic DNA
- 4.5.1. Global Synthetic DNA Market, 2021 - 2033 (USD Million)
- 4.5.1.1. Gene Synthesis
- 4.5.1.1.1. Global Gene Synthesis Market, 2021 - 2033 (USD Million)
- 4.5.1.2. Oligonucleotide Synthesis
- 4.5.1.2.1. Global Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
- 4.5.1.1. Gene Synthesis
- 4.5.1. Global Synthetic DNA Market, 2021 - 2033 (USD Million)
Chapter 5. DNA Manufacturing Market: Grade Business Analysis
- 5.1. Grade Segment Dashboard
- 5.2. Global DNA Manufacturing Market Grade Movement Analysis
- 5.3. Global DNA Manufacturing Market Size & Trend Analysis, by Grade, 2021 to 2033 (USD Million)
- 5.4. GMP Grade
- 5.4.1. Global GMP Grade Market, 2021 - 2033 (USD Million)
- 5.5. R&D Grade
- 5.5.1. Global R&D Grade Market, 2021 - 2033 (USD Million)
Chapter 6. DNA Manufacturing Market: Application Business Analysis
- 6.1. Application Segment Dashboard
- 6.2. Global DNA Manufacturing Market Application Movement Analysis
- 6.3. Global DNA Manufacturing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 6.4. Cell & Gene Therapy
- 6.4.1. Global Cell & Gene Therapy Market, 2021 - 2033 (USD Million)
- 6.5. Vaccines
- 6.5.1. Global Vaccines Market, 2021 - 2033 (USD Million)
- 6.6. Oligonucleotide-based Drugs
- 6.6.1. Global Oligonucleotide-based Drugs Market, 2021 - 2033 (USD Million)
- 6.7. Others
- 6.7.1. Global Others Market, 2021 - 2033 (USD Million)
Chapter 7. DNA Manufacturing Market: End Use Business Analysis
- 7.1. End Use Segment Dashboard
- 7.2. Global DNA Manufacturing Market End Use Movement Analysis
- 7.3. Global DNA Manufacturing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 7.4. Pharmaceutical and Biotechnology Companies
- 7.4.1. Global Pharmaceutical and Biotechnology Companies Devices Market, 2021 - 2033 (USD Million)
- 7.5. Academic & Research Institutes
- 7.5.1. Global Academic & Research Institutes Market, 2021 - 2033 (USD Million)
- 7.6. Contract Research Organizations
- 7.6.1. Global Contract Research Organizations Market, 2021 - 2033 (USD Million)
Chapter 8. Regional DNA Manufacturing Market: Region Estimates & Trend Analysis
- 8.1. North America
- 8.1.1. North America market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.1.2. U.S.
- 8.1.2.1. Key country dynamics
- 8.1.2.2. Competitive scenario
- 8.1.2.3. Regulatory Framework
- 8.1.2.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.1.3. Canada
- 8.1.3.1. Key country dynamics
- 8.1.3.2. Competitive scenario
- 8.1.3.3. Regulatory Framework
- 8.1.3.4. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.1.4. Mexico
- 8.1.4.1. Key country dynamics
- 8.1.4.2. Competitive scenario
- 8.1.4.3. Regulatory Framework
- 8.1.4.4. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.2. Europe
- 8.2.1. Europe market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.2.2. UK
- 8.2.2.1. Key country dynamics
- 8.2.2.2. Competitive scenario
- 8.2.2.3. Regulatory Framework
- 8.2.2.4. UK market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.2.3. Germany
- 8.2.3.1. Key country dynamics
- 8.2.3.2. Competitive scenario
- 8.2.3.3. Regulatory Framework
- 8.2.3.4. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.2.4. France
- 8.2.4.1. Key country dynamics
- 8.2.4.2. Competitive scenario
- 8.2.4.3. Regulatory Framework
- 8.2.4.4. France market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.2.5. Italy
- 8.2.5.1. Key country dynamics
- 8.2.5.2. Competitive scenario
- 8.2.5.3. Regulatory Framework
- 8.2.5.4. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.2.6. Spain
- 8.2.6.1. Key country dynamics
- 8.2.6.2. Competitive scenario
- 8.2.6.3. Regulatory Framework
- 8.2.6.4. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.2.7. Norway
- 8.2.7.1. Key country dynamics
- 8.2.7.2. Competitive scenario
- 8.2.7.3. Regulatory Framework
- 8.2.7.4. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.2.8. Sweden
- 8.2.8.1. Key country dynamics
- 8.2.8.2. Competitive scenario
- 8.2.8.3. Regulatory Framework
- 8.2.8.4. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.2.9. Denmark
- 8.2.9.1. Key country dynamics
- 8.2.9.2. Competitive scenario
- 8.2.9.3. Regulatory Framework
- 8.2.9.4. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.3. Asia Pacific
- 8.3.1. Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.3.2. Japan
- 8.3.2.1. Key country dynamics
- 8.3.2.2. Competitive scenario
- 8.3.2.3. Regulatory Framework
- 8.3.2.4. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.3.3. China
- 8.3.3.1. Key country dynamics
- 8.3.3.2. Competitive scenario
- 8.3.3.3. Regulatory Framework
- 8.3.3.4. China market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.3.4. India
- 8.3.4.1. Key country dynamics
- 8.3.4.2. Competitive scenario
- 8.3.4.3. Regulatory Framework
- 8.3.4.4. India market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.3.5. Thailand
- 8.3.5.1. Key country dynamics
- 8.3.5.2. Competitive scenario
- 8.3.5.3. Regulatory Framework
- 8.3.5.4. Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.3.6. South Korea
- 8.3.6.1. Key country dynamics
- 8.3.6.2. Competitive scenario
- 8.3.6.3. Regulatory Framework
- 8.3.6.4. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.3.7. Australia
- 8.3.7.1. Key country dynamics
- 8.3.7.2. Competitive scenario
- 8.3.7.3. Regulatory Framework
- 8.3.7.4. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.4. Latin America
- 8.4.1. Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.4.2. Brazil
- 8.4.2.1. Key country dynamics
- 8.4.2.2. Competitive scenario
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Argentina
- 8.4.3.1. Key country dynamics
- 8.4.3.2. Competitive scenario
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.5. Middle East & Africa
- 8.5.1. Middle East & Africa market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.5.2. South Africa
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Competitive scenario
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.5.3. Saudi Arabia
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Competitive scenario
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.5.4. UAE
- 8.5.4.1. Key country dynamics
- 8.5.4.2. Competitive scenario
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.5.5. Kuwait
- 8.5.5.1. Key country dynamics
- 8.5.5.2. Competitive scenario
- 8.5.5.3. Regulatory Framework
- 8.5.5.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Company Categorization
- 9.2. Strategy Mapping
- 9.3. Company Market Position Analysis, 2025
- 9.4. Company Profiles/Listing
- 9.4.1. Charles River Laboratories, Inc.
- 9.4.1.1. Overview
- 9.4.1.2. Financial Performance
- 9.4.1.3. Service Benchmarking
- 9.4.1.4. Strategic Initiatives
- 9.4.2. VGXI, Inc.
- 9.4.2.1. Overview
- 9.4.2.2. Financial Performance
- 9.4.2.3. Service Benchmarking
- 9.4.2.4. Strategic Initiatives
- 9.4.3. Danaher Corporation (Aldevron)
- 9.4.3.1. Overview
- 9.4.3.2. Financial Performance
- 9.4.3.3. Service Benchmarking
- 9.4.3.4. Strategic Initiatives
- 9.4.4. Thermo Fisher Scientific Inc.
- 9.4.4.1. Overview
- 9.4.4.2. Financial Performance
- 9.4.4.3. Service Benchmarking
- 9.4.4.4. Strategic Initiatives
- 9.4.5. Lonza
- 9.4.5.1. Overview
- 9.4.5.2. Financial Performance
- 9.4.5.3. Service Benchmarking
- 9.4.5.4. Strategic Initiatives
- 9.4.6. GenScript
- 9.4.6.1. Overview
- 9.4.6.2. Financial Performance
- 9.4.6.3. Service Benchmarking
- 9.4.6.4. Strategic Initiatives
- 9.4.7. Catalent, Inc.
- 9.4.7.1. Overview
- 9.4.7.2. Financial Performance
- 9.4.7.3. Service Benchmarking
- 9.4.7.4. Strategic Initiatives
- 9.4.8. Wuxi AppTec
- 9.4.8.1. Overview
- 9.4.8.2. Financial Performance
- 9.4.8.3. Service Benchmarking
- 9.4.8.4. Strategic Initiatives
- 9.4.9. Kaneka Corp.
- 9.4.9.1. Overview
- 9.4.9.2. Financial Performance
- 9.4.9.3. Service Benchmarking
- 9.4.9.4. Strategic Initiatives
- 9.4.10. Eurofins Genomics
- 9.4.10.1. Overview
- 9.4.10.2. Financial Performance
- 9.4.10.3. Service Benchmarking
- 9.4.10.4. Strategic Initiatives
- 9.4.1. Charles River Laboratories, Inc.
